(24/7 MARKET NEWS) – Axcella Therapeutics (Nasdaq: AXLA) announced, this morning, that it received regulatory guidance from the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA), supporting a single trial that could serve as the registration trial for patients with Long COVID fatigue, and aligning on key measurements, including primary endpoint and trial design. The company also submitted an Investigational New Drug (IND) Application to the U.S. Food and Drug Administration (FDA) for a Phase 2b/3 trial.
Axcella Therapeutics is trading at $0.63, 20-cents higher (+46.51%), on volume of 7.6 million shares traded.
Its 52-week range is $0.1621 to $2.89. Its premarket high is $0.89.
View source version: https://www.businesswire.com/news/home/20230123005745/en/
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
